A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome

被引:55
作者
Aggarwal, Rohit [1 ]
Dhillon, Namrata [1 ]
Fertig, Noreen [1 ]
Koontz, Diane [1 ]
Qi, Zengbiao [1 ]
Oddis, Chester V. [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA
关键词
ANTISYNTHETASE SYNDROME; ANTISYNTHETASE AUTOANTIBODY; POLYMYOSITIS; DERMATOMYOSITIS; ANTINUCLEAR ANTIBODY; CYTOPLASMIC ANTIBODY STAINING; TRANSFER-RNA-SYNTHETASE; IDIOPATHIC INFLAMMATORY MYOPATHIES; INTERSTITIAL LUNG-DISEASE; SYSTEMIC-SCLEROSIS; DERMATOMYOSITIS; POLYMYOSITIS; RITUXIMAB; SURVIVAL; FEATURES; UPDATE;
D O I
10.3899/jrheum.160618
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the utility of anticytoplasmic autoantibody (anti-CytAb) in antisynthetase antibody-positive (anti-SynAb+) patients. Methods. Anti-SynAb+ patients were evaluated for antinuclear antibody (ANA) and anti-CytAb [cytoplasmic staining on indirect immunofluorescence (IIF)] positivity. Anti-SynAb+ patients included those possessing anti-Jo1 and other antisynthetase autoantibodies. Control groups included scleroderma, systemic lupus erythematosus, Sjogren syndrome, rheumatoid arthritis, and healthy subjects. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy of anti-CytAb, and ANA were assessed. Anti-CytAb and ANA testing was done by IIF on human epithelial cell line 2, both reported on each serum sample without knowledge of the clinical diagnosis or final anti-SynAb results. Results. Anti-SynAb+ patients (n = 202; Jo1, n = 122; non-Jo1, n = 80) between 1985-2013 with available serum samples were assessed. Anti-CytAb showed high sensitivity (72%), specificity (89%), NPV (95%), and accuracy (86%), but only modest PPV (54%) for anti-SynAb positivity. In contrast, ANA showed only modest sensitivity (50%) and poor specificity (6%), PPV (9%), NPV (41%), and accuracy (12%). Positive anti-CytAb was significantly greater in the anti-SynAb+ patients than ANA positivity (72% vs 50%, p < 0.001), and 81/99 (82%) ANA-negative patients in the anti-SynAb+ cohort had positive anti-CytAb. In contrast, the control groups showed high rates for ANA positivity (93.5%), but very low rates for anti-CytAb positivity (11.5%). Combining anti-CytAb or Jo1 positivity showed high sensitivity (92%) and specificity (89%) for identification of anti-SynAb+ patients. Conclusion. Assessing patients for anti-CytAb serves as an excellent screen for anti-SynAb+ patients using simple IIF. Cytoplasmic staining should be assessed and reported for patients suspected of having antisynthetase syndrome and a negative ANA should not be used to exclude this diagnosis.
引用
收藏
页码:223 / 229
页数:7
相关论文
共 31 条
[1]   Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab [J].
Aggarwal, Rohit ;
Oddis, Chester V. ;
Goudeau, Danielle ;
Koontz, Diane ;
Qi, Zengbiao ;
Reed, Ann M. ;
Ascherman, Dana P. ;
Levesque, Marc C. .
RHEUMATOLOGY, 2016, 55 (06) :991-999
[2]   Anti-signal recognition particle autoantibody ELISA validation and clinical associations [J].
Aggarwal, Rohit ;
Oddis, Chester V. ;
Goudeau, Danielle ;
Fertig, Noreen ;
Metes, Ilinca ;
Stephens, Chad ;
Qi, Zengbiao ;
Koontz, Diane ;
Levesque, Marc C. .
RHEUMATOLOGY, 2015, 54 (07) :1194-1199
[3]   Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients [J].
Aggarwal, Rohit ;
Cassidy, Elaine ;
Fertig, Noreen ;
Koontz, Diane Carol ;
Lucas, Mary ;
Ascherman, Dana P. ;
Oddis, Chester V. .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) :227-232
[4]   Anti-U3 RNP Autoantibodies in Systemic Sclerosis [J].
Aggarwal, Rohit ;
Lucas, Mary ;
Fertig, Noreen ;
Oddis, Chester V. ;
Medsger, Thomas A., Jr. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (04) :1112-1118
[5]   Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia [J].
Betteridge, Z. ;
Gunawardena, H. ;
North, J. ;
Slinn, J. ;
McHugh, N. .
RHEUMATOLOGY, 2007, 46 (06) :1005-1008
[6]   POLYMYOSITIS AND DERMATOMYOSITIS .2. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) :403-407
[7]   POLYMYOSITIS AND DERMATOMYOSITIS .1. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) :344-347
[8]   International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results [J].
Damoiseaux, Jan ;
von Muhlen, Carlos A. ;
Garcia-De La Torre, Ignacio ;
Gabriel Carballo, Orlando ;
Cruvinel, Wilson de Melo ;
Carvalho Francescantonio, Paulo Luiz ;
Fritzler, Marvin J. ;
Herold, Manfred ;
Mimori, Tsuneyo ;
Satoh, Minoru ;
Andrade, Luis E. C. ;
Chan, Edward K. L. ;
Conrad, Karsten .
AUTOIMMUNITY HIGHLIGHTS, 2016, 7 (01) :1-8
[9]   Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies [J].
Dugar, M. ;
Cox, S. ;
Limaye, V. ;
Blumbergs, P. ;
Roberts-Thomson, P. J. .
INTERNAL MEDICINE JOURNAL, 2011, 41 (09) :674-679
[10]   Clinical and Serologic Characterization of an Argentine Pediatric Myositis Cohort: Identification of a Novel Autoantibody (anti-MJ) to a 142-kDa Protein [J].
Espada, Graciela ;
Maldonado Cocco, Jose A. ;
Fertig, Noreen ;
Oddis, Chester V. .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) :2547-2551